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Abstract
Background: To investigate the effect of physician- and patient-specific feedback with benchmarking on the
quality of care in adults with type 2 diabetes mellitus (T2DM).
Methods: Study centres in six European countries were randomised to either a benchmarking or control group.
Physicians in both groups received feedback on modifiable outcome indicators (glycated haemoglobin [HbA1c],
glycaemia, total cholesterol, high density lipoprotein-cholesterol, low density lipoprotein [LDL]-cholesterol and
triglycerides) for each patient at 0, 4, 8 and 12 months, based on the four times yearly control visits recommended
by international guidelines. The benchmarking group also received comparative results on three critical quality
indicators of vascular risk (HbA1c, LDL-cholesterol and systolic blood pressure [SBP]), checked against the results of
their colleagues from the same country, and versus pre-set targets. After 12 months of follow up, the percentage
of patients achieving the pre-determined targets for the three critical quality indicators will be assessed in the two
groups.
Results: Recruitment was completed in December 2008 with 3994 evaluable patients.
Conclusions: This paper discusses the study rationale and design of OPTIMISE, a randomised controlled study, that
will help assess whether benchmarking is a useful clinical tool for improving outcomes in T2DM in primary care.
Trial registration: NCT00681850
Background
Physicians in Europe and throughout the world are
diagnosing and treating a growing number of patients
with type 2 diabetes mellitus (T2DM). The International
Diabetes Federation estimates that approximately 55
million people in Europe had diabetes in 2010 [1]. Over
90% of these are patients with T2DM, and management
of its associated complications already requires a signifi-
cant level of support in terms of financial costs and
healthcare utilisation [2]. In 2009 the healthcare expen-
diture for diabetes was estimated to account for 10% of
the total health budget in Europe [1] and this financial
burden, together with the accompanying social burden
associated with reduced quality of life and productivity
caused by the condition, its numerous comorbidities
and premature death, is undoubtedly set to rise over the
next decade.
Clinical research has shown that long-term complica-
tions of diabetes can be delayed or even prevented when
management by the healthcare team and the patient’s
self-management are optimised [3-5]. However, the
apparent inability to effectively translate this scientific
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evidence into real-life clinical practice represents a
major barrier to reducing the burden of diabetes com-
plications [6,7].
Western healthcare systems are currently in a transi-
tion phase; shifting towards organisational structures
that can deliver improved diabetes care specifically, and
chronic care in general [8,9]. T2DM is often used as
‘the’ test case for new models of care. The assumption is
that if an intervention works in as complex a disease as
T2DM, there is a fair likelihood that it will be effective
in other chronic conditions. Because the majority of
chronic illness care is performed within the primary
care setting, redesign of primary care has been proposed
in an attempt to close the gap between current practices
and optimal standards [10]. How such a redesign might
be accomplished is the subject of ongoing research and
socio-economic debate, and in this process the Chronic
Care Model is often used as a conceptual framework
[11-13]. This model identifies six essential elements that
impact upon chronic care: (i) community resources and
policies, (ii) healthcare organisation, (iii) self-manage-
ment support, (iv) delivery system design, (v) decision
support, and (vi) clinical information systems [12].
Initial evidence demonstrates that the Chronic Care
Model can improve chronic care and, in some cases,
reduce healthcare costs [8,9,13]. However, more
research is needed to substantiate the relative effective-
ness of the components of this model.
One element of the Chronic Care Model that has not
been studied extensively, but which nevertheless may
offer a realistic opportunity to improve chronic care, is
the use of clinical information systems. These include
reminder systems that help primary care teams comply
with practice guidelines, and feedback to physicians
showing how they are performing with regard to quality
of care indicators. Practice recommendations (which
may be based on national or international guidelines)
are generally used as a reference for comparison when
providing feedback.
Benchmarking, a technique used for quality manage-
ment in industry since the 1980s, has only recently been
introduced into the clinical setting. It consists of mea-
suring the clinical performance of the healthcare deliv-
ered by an individual clinician or a clinic over a
specified period (termed the audit), comparing it with
the performance of a peer group or a group of similar
clinics (benchmarking), and transmitting this compari-
son back to the clinician or clinic (benchmarked feed-
back) (Figure 1). Benchmarking therefore encompasses
an intellectual, emotional and/or competitive stimulus
for change. It also offers an opportunity to break
through the isolation that many primary care physicians
encounter, as they are not routinely able to compare
their performance with that of their peers.
It would appear to be intuitively logical that if health-
care professionals were given feedback that their clinical
practice, and therefore their patient outcomes, was
inconsistent with that of their peers or accepted guide-
lines, they would modify their attitude and practice.
However, there are few published reports of randomised
studies investigating this approach in T2DM in primary
care, and the effectiveness of feedback and benchmark-
ing has not been definitively proven in a randomised,
controlled setting. OPTIMISE (OPtimal Type 2 dIabetes
Management Including benchmarking and Standard
trEatment) was designed as a randomised controlled
trial assessing the effect over a 12-month period of phy-
sician- and patient-specific feedback with benchmarking
on the quality of primary care in T2DM patients from
six European countries. The aim of the current paper is
to describe the rationale for, and methodology used in
the OPTIMISE study, including details of the bench-
marking and feedback process.
Methods
The original protocol developed in Belgium was subse-
quently adapted for extension to five other European
countries: Greece, Luxembourg, Portugal, Spain and the
UK. Patient recruitment began in March 2008 in Bel-
gium, and in September 2008 for the other countries.
Patients
All patients with T2DM (insulin treated or not), aged
≥18 years were eligible for the OPTIMISE study. Exclu-
sion criteria were patients with type 1 diabetes, gesta-
tional diabetes, patients who were hospitalised for
diabetes regulation or who were members of the Belgian
Diabetes Convention (i.e. hospital-based diabetes centres
already participating in a quality assurance programme
Figure 1 Example of benchmarking and feedback process.
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with benchmarked feedback). The definition of diabetes
used was a fasting plasma glucose test of ≥126 mg/dL.
Study design
This randomised controlled trial was performed in
accordance with the Declaration of Helsinki and ICH/
Good Clinical Practice and applicable regulatory
requirements [14]. The study was sponsored by Astra-
Zeneca. Written, informed consent was obtained for all
patients before initiation into the study. The OPTIMISE
study is registered at ClinicalTrials.gov (NCT00681850).
The aim of the study was to assess the impact of
benchmarking on the quality of T2DM care, by deter-
mining, as the primary objective, the percentage of
patients in the benchmarking group achieving, after 12
months of follow up, pre-set targets of three critical
quality indicators (glycated haemoglobin [HbA1c], low-
density lipoprotein [LDL]-cholesterol and systolic BP
[SBP]) versus the control group. The null hypothesis
was that the percentage of patients at target after 12
months of follow up in the benchmarking and the con-
trol groups would be equal. Secondary objectives
included determining the percentage of patients achiev-
ing the pre-set targets of the critical quality indicators
and glycaemia versus baseline; determining the percen-
tage improvement of the critical quality indicators and
glycaemia versus baseline; and to follow up evolution
markers of preventative screening (retinopathy, neuropa-
thy, dietary counselling, microalbuminuria, smoking
habits, body mass index [BMI], and physical activity).
Centres or sites were selected on the basis of having
sufficient patients with diabetes in their practice and
with investigators that were motivated to fulfil the
administrative procedures linked to the study. Centres
or sites were randomised by a central randomisation
procedure to either a benchmarking group or a control
group. To ensure that country-specific treatment prac-
tices were reflected in the study population, the centres
or sites involved in the management of diabetes that
were recruited, consisted of general practitioner or hos-
pital-based outpatient clinics. Recruitment for the study
began initially in Belgium with a randomisation ratio of
1:1. Each centre was expected to recruit 8-12 patients;
however, some centres enrolled 15-20 patients. The
adapted sample size analysis showed that a power of
79% was achieved for the parameter blood pressure and
a significance level of 0.05 was achieved for the para-
meters HbA1c and total cholesterol. As sufficiently high
numbers of physicians were recruited in Belgium, this
subsequently allowed a 3:1 randomisation ratio of
benchmarked to control practices in the other countries,
which was deemed more attractive to the participating
physicians. All physicians involved in the study contin-
ued with the routine monitoring, treatment and
counselling of their patients with T2DM. Over the
course of the study, physicians in both groups received
the results of modifiable outcome indicators (HbA1c,
fasting glycaemia, total cholesterol, high-density lipopro-
tein [HDL]-cholesterol, LDL-cholesterol and triglycer-
ides [TG]; determined in a central laboratory).
Physicians in the benchmarking group additionally
received information on the level of control of the criti-
cal quality indicators of their individual patients, anon-
ymously compared with the results of their colleagues
from the same country, and compared with target levels
(Figure 2). This benchmarked feedback was provided
every 4 months, corresponding to three- to four-times
yearly control visits, as recommended by international
guidelines [15]. The study recruitment and initiation
visit was defined as Visit 1 out of the four visits.
Patient evaluation and quality indicators
Each patient was followed for 12 months. Overnight
fasting levels of HbA1c, glycaemia, total cholesterol,
HDL- and LDL-cholesterol and TG were determined at
each visit. Blood samples were sent to a central labora-
tory (Bio Analytical Research Corporation [BARC],
Ghent, Belgium) for analysis. HbA1c was measured
using ion-exchange high performance liquid chromato-
graphy (HPLC) (Adams A1c HA8160, Arkray, Kyoto,
Japan). LDL-cholesterol data from evaluable patients
was estimated using Friedewald’s formula, which uses
total cholesterol, HDL-cholesterol and fasting TG when
the latter are < 400 mg/dL. Urine was analysed for
microalbuminuria at Visits 1 and 4 using an immuno-
turbidimetric assay (Modular P analyser, Roche Diagnos-
tics, Mannheim, Germany).
Casual (resting) BP, waist circumference, weight and
height were measured by the physician at each visit. BP
was measured using a manometer with an appropriately
sized cuff with the patient in the sitting position for at
least 5 minutes prior to the reading. A mean value was
determined from three successive readings and
recorded. Waist circumference was measured using a
measuring tape placed around the patient’s abdomen at
the level of the iliac crest and at the end of normal
expiration. Patients wore light clothing and no shoes
during weight measurement - values were rounded up
to the nearest kg from 0.5 kg. Patients wore no shoes
during height measurement - values were rounded up to
the nearest cm from 0.5 cm.
A history of proteinuria at baseline was established
from proteinuria levels in the patient’s medical records
and computed in the electronic Case Report Form
(eCRF). Smoking status was also recorded in the eCRF
as smoker/ex-smoker/non-smoker, together with the
number of cigarettes, cigars or pipes that the patient
was smoking, or had smoked per day. In addition,
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records were kept of whether or not a needs assessment
for low-dose aspirin therapy (as an antiplatelet agent)
had been performed during the 12 months of the study,
as at the time the protocol was written, this was a
recommended parameter to be taken into consideration
for patients with T2DM [16]. Optional assessment by
the treating physician at each visit of the degree of phy-
sical activity could be carried out using a step counter.
Figure 2 Study flow chart. CRF, case report form; IC, informed consent.
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A four-point verbal rating scale (VRS) was used to
assess total physical activity with the following criteria;
no weekly activity; only limited physical activity during
most weeks; intense physical activity (activity that gives
rise to shortness of breath, tachycardia and sweating)
during at least 20 minutes, once to twice a week; intense
physical activity (activity that gives rise to shortness of
breath, tachycardia and sweating) during at least 20
minutes, ≥3 times a week.
Critical quality indicators used for benchmarking were
HbA1c, LDL-cholesterol and SBP. Secondary quality
indicators, not used for benchmarking, were blood glu-
cose, TG, total and HDL-cholesterol, diastolic blood
pressure (DBP), BMI, waist circumference and smoking
status. Whether or not dietary advice had been given
(and by whom), and whether screening for retinopathy
and foot examination had been performed during the 12
months of the investigation, were also recorded and
analysed as secondary quality indicators but were not
part of the benchmarking feedback.
Target setting for benchmarking
The targets set for the critical quality indicators (HbA1c,
LDL-cholesterol and SBP) used for benchmarking were
based on international guidelines [16-18], and, when
deemed necessary, adapted by the study steering com-
mittee in order to be consensual to the participating
countries (Table 1).
For physicians in the benchmarking group, bench-
marked feedback was given to each practice for both the
pooled patient population at that practice, and at an
individual patient level (Figure 3). A bi-modal response
was given (good, too high) for each of the critical quality
indicators, signifying whether or not the patient/clinic
had achieved targets. In Belgium, the National Steering
Committee opted for a tri-modal response: HbA1c ≤7.0%
= excellent, 7.1-7.5% = borderline, > 7.5% = too high;
SBP < 130 mmHg = excellent, 130-139 mmHg = bor-
derline, ≥140 mmHg = too high; LDL-cholesterol < 80
mg/dL = excellent, 80-99 mg/dL = good, ≥100 mg/dL =
too high (< 70 mg/dL = excellent in secondary
prevention).
Statistical considerations
In this study, all patients treated by an investigator
received the same type of follow up (either
benchmarking or standard). Since each investigator may
have a particular approach for monitoring, counselling
and treating their patients with T2DM, it was expected
that this might result in an investigator or cluster effect.
The extent of this effect is reflected by the Intracluster
Correlation Coefficient (ICC) which, according to the
literature, varies for BP between 0.05 and 0.10, indicat-
ing a clustering influence of 5-10% [19-21]. Of the three
critical quality indicators used for benchmarking, SBP
was expected to be the least well controlled at baseline.
Therefore, for the purposes of study sample size calcula-
tions, it was considered most important to be able to
demonstrate significance in the improvement in propor-
tion of patients achieving the pre-set targets for SBP.
For example in the Best study [22], blood pressure
was controlled in only 12.3% of patients at baseline;
however, the proportion of patients with their blood
pressure under control increased by 68.3% after 6
months of more intensive follow up. Due to the stric-
ter target (130/80 mmHg in the OPTIMISE study
compared with 140/90 mmHg) and the longer duration
of this study, an improvement of 88.7% could be
expected in the proportion of patients reaching blood
pressure targets in both groups, from 12.3% to 23.2%
in the control group and the benchmarking group
under the null hypothesis (the null hypothesis is that
the percentages in both groups are equal). There are
relatively few previous studies reporting the level of
improvement seen when benchmarking was used.
However, review of those available [23-27] suggest that
the level of improvement that might be expected
ranges from 15-51%. Based on these findings it was
estimated that the use of benchmarking in OPTIMISE
could further improve the level of blood pressure con-
trol by 32%, i.e from 23.2 to 30.6% (the alternative
hypothesis is that the percentage in the benchmarking
group is larger than in the control group). With 3000
evaluable patients in the benchmarking group (300
clusters of 10 patients) and 1000 patients in the con-
trol group (100 clusters of 10 patients), a two-sided Z
test (unpooled) would give 91%, 86% and 80% power
to detect a 74% difference between the proportion of
patients on target for SBP for an ICC of 0.05, 0.07 and
0.10 (between 5 and 10%).
As some centres included up to 20 patients, sample
size calculations were adapted. With 3000 evaluable
patients in the benchmarking group (200 clusters of 15
patients) and 1000 patients in the control group (67
clusters of 15 patients), there would be 96%, 93% and
88% power to detect a 74% difference between the pro-
portion of patients on target for SBP for an ICC of 0.05,
0.07 and 0.10, respectively, p = 0.05. With 3000 evalu-
able patients in the benchmarking group (150 clusters of
20 patients) and 1000 patients in the control group (50







All countries < 130* < 100† < 7.0
Belgium < 80†
*Patients with proteinuria < 125 mmHg
†Patients with existing coronary heart disease < 70 mg/dL
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clusters of 20 patients), there would be 93%, 88% and
81% power to detect a 74% difference between the pro-
portion of patients on target for SBP for an ICC of 0.05,
0.07 and 0.10, respectively, p = 0.05.
Descriptive statistics (mean, median, number of obser-
vations, standard deviation, standard error, 95% confi-
dence intervals - minimum and maximum) of all
primary and other variables will be tabulated. Given the
Figure 3 Example of benchmarking in OPTIMISE. Reproduced with permission from Whathealth.eu. SBP, systolic blood pressure.
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expected clustering of patients for each physician, multi-
level mixed modelling will be performed using SAS
GLINMIX for categorical variables (target attainment
after 12 months in the benchmarking group compared
with the control group, and target attainment after 12
months compared with baseline levels) and SAS Prox
MIX for continuous variables (mean percentage
improvement of HbA1c, LDL-cholesterol and SBP after
12 months follow up).
Results
Recruitment commenced on 6 March 2008 and finished
31 December 2008. The database lock date was 31
March 2010. A total of 4026 patients, of which 3994 are
evaluable, were enrolled from 370 sites across six coun-
tries in Europe. In the All Patients group, 55.1% were
male. The benchmarking group comprised 2484
patients; the control group comprised 1510 patients
(Table 2). Baseline demographics were similar for both
groups. Full results will be reported elsewhere.
Discussion
It is important to note that there is some confusion in
the literature between the terms feedback and bench-
marking. In the OPTIMISE study, benchmarking refers
to the process of comparing critical quality indicators
with the results of peers. Communicating these results
to the physicians will be referred to as benchmarked
feedback or feedback with benchmarking, to distinguish
it from communicating the levels of the quality indica-
tors alone to the physicians.
There is emerging evidence from non-randomised
controlled trials (non-RCTs) that feedback and bench-
marking exert a positive effect on process, outcome and
overall provision of diabetes care [28-31]. However, fol-
low up over time without specific interventions has also
demonstrated improvements in diabetes care [32,33].
Thus, it is difficult in non-RCTs to ascertain whether
any detected improvements in care are due to the speci-
fic intervention applied.
There is limited evidence from RCTs on the effects of
feedback on quality of care in T2DM in particular, and
in chronic care in general. Furthermore, evidence from
RCTs on the effect of benchmarking is virtually non-
existent. A recent systematic literature review [34] iden-
tified 10 RCTs evaluating feedback only, but not bench-
marking, in T2DM in primary care. The studies were
very heterogeneous in aims and designs and a meta-ana-
lysis of these trials was not considered feasible. A variety
of outcome measures were studied. Feedback in the
T2DM studies seemed to improve process markers such
as foot examinations, eye examinations and HbA1c mea-
surements. Clinical effect markers such as BP, levels of
HbA1c and cholesterol were only assessed in three stu-
dies, showing small positive effects on BP in three, on
HbA1c in two, and on cholesterol in one study. Since
this systematic review, two additional RCTs of feedback
in T2DM (one using benchmarking) were published
[35,36]. However, neither of these studies showed any
effect on either process or outcome measures. There-
fore, while some studies suggest that feedback can lead
to a small improvement in testing rates, overall it seems
that it rarely changes downstream clinical outcomes
such as HbA1c levels. The evidence from the literature
therefore suggests that clinical inertia is not driven by
physicians’ knowledge deficit, but is due to reluctance
among physicians to make management changes. There-
fore, benchmarking, using comparisons with peer per-
formance, could potentially add an emotional-
competitive drive to overcome this barrier.
There are limited publications on the effects of bench-
marking on quality of care in T2DM. A systematic
review of controlled trials evaluating the effectiveness of
various interventions to improve T2DM in primary care
found that benchmarking improved diabetes care provi-
sion in settings characterised by poor overall standard of
care at baseline [37]. However, clinical outcomes were
rarely assessed, and no statistically significant improve-
ments were demonstrated. A meta-analysis investigating
benchmarking in clinical care found a small but signifi-
cant positive effect on outcomes [38]. This analysis indi-
cated that the effectiveness of benchmarking was
improved when the benchmarked feedback was written
rather than verbal or graphical, and when it was pro-
vided more frequently. In addition, providing combined
group- and individual-level feedback appeared to have a
positive effect.
There are few published reports of randomised studies
investigating the effectiveness of benchmarking in
T2DM in primary care. In a small study comparing two
types of benchmarking interventions, 70 community
physicians in the USA were randomly assigned to
receive a multi-modal quality improvement intervention,
including physician-specific benchmarking feedback or
an identical intervention plus Achievable Benchmarks of
Care (ABC) feedback [23]. In the physician-specific
Table 2 OPTIMISE Study: Number of patients
participating in each country
Country Benchmarking Control All patients
Belgium 1146 1044 2190
Greece 570 227 797
Luxembourg 136 62 198
Portugal 134 51 185
Spain 257 55 312
UK 241 71 312
Total 2484 1510 3994
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benchmarking feedback only group, the mean perfor-
mance of the individual physicians on patient outcomes
was compared with the performance of their anon-
ymised peers. In the ABC feedback group, the individual
performance of the physicians was compared with stan-
dards of excellence attained by top performers in the
peer group. Odds ratios (ORs) for the ABC group vs
comparison physicians who delivered appropriate care
after the intervention were 1.57 (95% confidence interval
[CI], 1.26,1.96) for influenza vaccination, 1.33 (95% CI,
1.05,1.69) for foot examination, and 1.33 (95% CI,
1.04,1.69) for long-term glucose control measurement.
For serum cholesterol and TG, the effect of ABC feed-
back was not statistically significant. Another rando-
mised trial that examined simultaneous benchmarking
of US physicians and their patients failed to demonstrate
improved safety or quality of care [36].
The paucity of controlled clinical trial evidence in
T2DM provided the rationale for the initiation of OPTI-
MISE. The original protocol was developed in Belgium,
based on a long-standing large scale feedback and bench-
marking project in specialised diabetes centres, the
‘Initiative for the Promotion of Quality and Epidemiology
of Diabetes mellitus (IQED)’ [39]. The OPTIMISE trial
resulted from an interest to carry this initiative into the
primary care setting. Because an intervention tested in
different healthcare systems would provide greater infor-
mation value, the OPTIMISE study was extended to five
other countries in Europe. The main differences between
the OPTIMISE design and the Belgian IQED initiative
are that OPTIMISE was (i) performed in a primary care
setting, (ii) utilised a RCT design with a comparative con-
trol group that did not receive benchmarking feedback,
(iii) used a central laboratory, and (iv) focused on a smal-
ler set of quality indicators. To minimise measurement
variability, a central laboratory was identified for measur-
ing HbA1c and lipids in the OPTIMISE trial. In real-life
clinical practice, routine laboratory measurements could
be used for benchmarking, provided the laboratories per-
forming the analyses have suitable accredited quality
assurance programmes, e.g. for HbA1c measurement [36].
Experience from the IQED initiative indicated that using
a large dataset may somehow dilute the impact of bench-
marking. The use of a limited number of critical quality
indicators in OPTIMISE enabled the study investigators
to provide benchmarking in a simple format, with suc-
cinct, easily interpretable messages accompanied by an
immediately actionable item. In addition, the IQED
initiative provided feedback every 18 months, while in
OPTIMISE feedback was given every 4 months, as more
frequent feedback was shown to augment the effect on
outcomes [40].
The OPTIMISE trial has several strengths. Contrary to
many studies in the field of quality improvement, this
study uses a monofactorial intervention allowing its
potential effects to be easily studied and contextualised.
It randomises at the clinic level and not at the patient
level to avoid confounding effects from physicians hav-
ing both intervention and control patients. Results are
analysed at the patient level as this is more clinically
meaningful. Importantly, the RCT design avoids any
positive effect bias that may be induced by increased
attention caused by participation in a study, or by
selecting more motivated physicians, or by overall
changes in T2DM care over the study period. A possible
confounder of the study may be the frequency of deter-
mining the quality indicators, which was pre-specified in
the protocol. Frequency of testing may have increased
for both groups of patients in the study compared with
their testing frequency prior to study initiation. This
alone may have led to an improvement in target attain-
ment in both groups. One possible limitation of the
study is that LDL-cholesterol levels were estimated
using Friedewald’s formula, rather than being directly
measured. However, this reflects real-life clinical prac-
tice. A further limitation may be the requirement to
establish a history of proteinuria from patient medical
records, as proteinuria may not be routinely tested for
and recorded. In addition to investigating the effects of
benchmarking, the OPTIMISE study offers an opportu-
nity to obtain comparable data on the quality of primary
care received by patients with T2DM in six European
countries. It is difficult to obtain comparable data across
different European countries due to heterogeneity in
data collection. Therefore, the OPTIMISE data have the
potential to offer a particularly useful resource for Eur-
opean healthcare providers, and help inform diabetes
care policy decisions at the European level along with
other initiatives such as the European Core Indicators in
Diabetes project (EUCID), which aims to create a plat-
form to collect and analyse data on health status and
care delivery for diabetes in Europe [41].
In summary, although feedback with benchmarking is
a promising tool for quality improvement in chronic
care in general, and in diabetes care specifically, there is
a striking lack of clinical evidence from controlled trials.
The results from OPTIMISE may have the potential to
contribute to filling this gap.
Acknowledgements
OPTIMISE is funded by AstraZeneca.
Members of the International Steering Committee: Michel P Hermans, Carlos
Brotons, Moses Elisaf, Georges Michel, Erik Muls.
The authors meet criteria for authorship as recommended by the
International Committee of Medical Journal Editors (ICMJE), were fully
responsible for all content and editorial decisions, and were involved at all
stages of manuscript development. The authors received no compensation
related to the development of the manuscript. The authors thank Kerrie
O’Rourke, PhD, and Nikki Kendrick, BSc, from QXV Communications for their
assistance in the manuscript preparation and Claire Marie Seymour, PhD,
Nobels et al. Cardiovascular Diabetology 2011, 10:82
http://www.cardiab.com/content/10/1/82
Page 8 of 10
from XPE Pharma and Science for editorial assistance and manuscript co-
ordination. This was funded by AstraZeneca Belgium.
Author details
1Endocrinologie, OLV Ziekenhuis, Moorselbaan 164, B-9300 Aalst, Belgium.
2Corilus, Hogenakkerhoer 5 - 9150, Kruibeke, Belgium. 3Research Unit, EAP
Sardenya-IIB Sant Pau, Sardenya, 466. 08025, Barcelona, Spain. 4Department
of Internal Medicine, School of Medicine, University of Ioannina, 451 10
Ioannina, Greece. 5Endocrinology & Nutrition, Cliniques universitaires St-Luc,
DIAB 54.74 Tour Claude Bernard +1 avenue Hippocrate 54, B-1200 Brussels,
Belgium. 6Endocrinology, Centre Hospitalier de Luxembourg, 4 rue Barblé, L-
1210 Luxembourg. 7Department of Endocrinology, UZ Gasthuisberg,
Herestraat 49, B-3000 Leuven, Belgium.
Authors’ contributions
FN participated in the conception of the study, and helped to draft the
manuscript. ND helped to draft the manuscript, and provided the literature
analysis regarding the effect of feedback and benchmarking on the quality
of diabetes care. CB participated in the discussion of results and drafting the
manuscript. ME participated in the design of the study and in drafting the
manuscript. EM participated in the conception of the study, and drafted the
manuscript. GM participated in evaluating the study results and drafting the
manuscript. MH was responsible for the conception of the study, and
participated in its design and coordination and helped to draft the
manuscript. All authors have read and approved the final manuscript.
Competing interests
FN has received speaker fees, advisory board payments and has been
provided with travel to scientific meetings by various pharmaceutical
companies.
CB has received speaker fees and advisory board payments from various
pharmaceutical companies.
ME has received speaker honoraria, consulting fees and research funding
from AstraZeneca, Schering Plough, Pfizer, Solvay and Fournier, and has
participated in clinical trials with AstraZeneca, Merck, Sanofi-Synthelabo,
Solvay and Fournier,
EM has received speaker fees and advisory board payments from various
pharmaceutical companies.
GM has received speaker fees, advisory board payments and has been
provided with travel to scientific meetings by various pharmaceutical
companies.
ND has received advisory board payments.
MH has served on an advisory panel and/or received speaker’s honoraria or
travel grants from Abbott, AstraZeneca, BMS, Boehringer Ingelheim, GSK, Eli
Lilly, Menarini, Novartis, Novo Nordisk, sanofi aventis and Takeda.
Received: 11 April 2011 Accepted: 22 September 2011
Published: 22 September 2011
References
1. IDF Diabetes Atlas. , 4[http://www.diabetesatlas.org/].
2. Jönsson B, CODE-2 Advisory Board: Revealing the cost of Type II diabetes
in Europe. Diabetologia 2002, 45:S5-S12.
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). The Lancet 1998, 352:837-853.
4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A,
Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists’
Collaborators: Efficacy and safety of cholesterol lowering treatment:
prospective meta-analysis of data from 90,056 participants in 14
randomized trials of statins. Lancet 2005, 366:1267-1278.
5. Fuller J, Stevens LK, Chaturvedi N, Holloway JF: Antihypertensive therapy
for preventing cardiovascular complications in people with diabetes
mellitus. Cochrane Database Syst Rev 2000, 2:CD002188.
6. Institute of Medicine: Crossing the quality chasm: a new health system for the
21st century Washington, DC: National Academy Press; 2001.
7. Davidson M: How our current medical care system fails people with
diabetes. Lack of timely, appropriate clinical decisions. Diabetes Care
2009, 32:370-372.
8. Weingarten S, Henning J, Badamgarav E, Knight K, Hasselblad V, Gano A Jr,
Ofman J: Interventions used in disease management programmes for
patients with chronic illness-which ones work? Meta-analysis of
published reports. BMJ 2002, 325:925-932.
9. Shojania K, Ranji S, McDonald K, Grimshaw J, Sundaram V, Rushakoff R,
Owens D: Effects of Quality Improvement Strategies for Type 2 Diabetes
on Glycemic Control. A Meta-Regression Analysis. JAMA 2006,
296:427-440.
10. Maier M, Knopp A, Pusarnig S, Rurik I, Orozco D, Yaman H, van Eygen L,
European Forum for Diabetes Care: Position Paper: Diabetes in Europe:
role and contribution of Primary Care. Qual Prim Care 2008, 16:197-207.
11. Bodenheimer T, Lorig K, Holman H, Grumbach K: Patient self-management
of chronic disease in primary care. JAMA 2002, 288:2469-2475.
12. Bodenheimer T, Wagner E, Grumbach K: Improving primary care for
patients with chronic illness. JAMA 2002, 288:1775-1779.
13. Bodenheimer T, Wagner E, Grumbach K: Improving primary care for
patients with chronic illness: the Chronic Care Model, Part 2. JAMA 2002,
288:1909-1914.
14. European Medicines Agency: ICH Topic E 6 (R1). Guidance On Good Clinical
Practice (CPMP/ICH/135/95) [http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2009/09/WC500002874.pdf].
15. IDF Clinical Guidelines Task Force: Global guideline for Type 2 diabetes.
Brussels: International Diabetes Federation 2005.
16. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V,
Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D,
Redberg R, Stitzel KF, Stone NJ, American Heart Association; American
Diabetes Association: Primary prevention of cardiovascular diseases in
people with diabetes mellitus: a scientific statement from the American
Heart Association and the American Diabetes Association. Diabetes Care
2007, 30:162-172.
17. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R,
Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C,
Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z,
Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D,
Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A,
Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C,
Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S,
Tendera M, Widimsky P, Zamorano JL, Altiner A, Bonora E, Durrington PN,
Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML,
Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L,
Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoglu L, Wiklund O,
Zampelas A, European Society of Cardiology (ESC); European Association for
Cardiovascular Prevention and Rehabilitation (EACPR); Council on
Cardiovascular Nursing; European Association for Study of Diabetes (EASD);
International Diabetes Federation Europe (IDF-Europe); European Stroke
Initiative (EUSI); International Society of Behavioural Medicine (ISBM);
European Society of Hypertension (ESH); European Society of General
Practice/Family Medicine (ESGP/FM/WONCA); European Heart Network
(EHN): European guidelines on cardiovascular disease prevention in
clinical practice. Fourth Joint Task Force of the European Society of
Cardiology and Other Societies on Cardiovascular Disease Prevention in
Clinical Practice (Constituted by representatives of nine societies and by
invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl 2):E1-E40.
18. American Diabetes Association: Clinical Practice Recommendations.
Diabetes Care 2007, 30(Suppl 1):S1-S103.
19. Eccles MP, Whitty PM, Speed C, Steen IN, Vanoli A, Hawthorne GC,
Grimshaw JM, Wood LJ, McDowell D: A pragmatic cluster randomised
controlled trial of a Diabetes REcall And Management system: the
DREAM trial. Implement Sci 2007, 2:6.
20. Lachin JM: Biostatistical Methods New York: John Wiley & Sons; 2002.
21. Machin D, Campbell M, Fayers P, Pinol A: Sample Size Tables for Clinical
Studies Oxford: Blackwell Science; 1997.
22. Brohet C, De Backer G, Scheen AJ, Van Gaal LF, Duquenne V, Vissers E:
Belgian evaluation of screening and treatment of hish-risk patients
based on waist and age (Best study). Eur J Cardiac Prev Rehab 2005,
12:280.
23. Kiefe CI, Allison JJ, Williams OD, Person SD, Weaver MT, Weissman NW:
Improving quality improvement using achievable benchmarks for
physician feedback: a randomized controlled trial. JAMA 2001,
285:2871-2879.
Nobels et al. Cardiovascular Diabetology 2011, 10:82
http://www.cardiab.com/content/10/1/82
Page 9 of 10
24. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O:
Multifactorial intervention and cardiovascular disease in patients with
type 2 diabetes. N Engl J Med 2003, 348:383-393.
25. Merlani P, Garnerin P, Diby M, Ferring M, Ricou B: Quality improvement
report: Linking guideline to regular feedback to increase appropriate
requests for clinical tests: blood gas analysis in intensive care. BMJ 2001,
323:620-624.
26. Scholle SH, Roski J, Adams JL, Dunn DL, Kerr EA, Dugan DP, Jensen RE:
Benchmarking physician performance: reliability of individual and
composite measures. Am J Manag Care 2008, 14:833-838.
27. Jamtvedt G, Young JM, Kristoffersen DT, O’Brien MA, Oxman AD: Does
telling people what they have been doing change what they do? A
systematic review of the effects of audit and feedback. Qual Saf Health
Care 2006, 15:433-436.
28. de Grauw WJ, van Gerwen WH, van de Lisdonk EH, van den Hoogen HJ,
van den Bosch WJ, van Weel C: Outcomes of audit-enhanced monitoring
of patients with type 2 diabetes. J Fam Pract 2002, 51:459-464.
29. Valk GD, Renders CM, Kriegsman DM, Newton KM, Twisk JW, van Eijk JT,
van der WG, Wagner EH: Quality of care for patients with type 2 diabetes
mellitus in the Netherlands and the United States: a comparison of two
quality improvement programs. Health Serv Res 2004, 39:709-725.
30. Hunt JS, Siemienczuk J, Gillanders W, Leblanc BH, Rozenfeld Y, Bonin K,
Pape G: The impact of a physician-directed health information
technology system on diabetes outcomes in primary care: a pre- and
post-implementation study. Inform Prim Care 2009, 17:165-174.
31. Club Diabete Sicili@: Five-year impact of a continuous quality
improvement effort implemented by a network of diabetes outpatient
clinics. Diabetes Care 2008, 31:57-62.
32. Calvert M, Shankar A, McManus RJ, Lester H, Freemantle N: Effect of the
quality and outcomes framework on diabetes care in the United
Kingdom: retrospective cohort study. BMJ 2009, 338:b1870.
33. Kristensen JK, Lauritzen T: Quality indicators of type 2-diabetes
monitoring during 2000-2005. Ugeskr Laeger 2009, 171:130-134.
34. Guldberg T, Lauritzen T, Kristensen J, Vedsted P: The effect of feedback to
general practitioners on quality of care for people with type 2 diabetes.
A systematic review of the literature. BMC Family Practice 2009, 10:30.
35. Smith SA, Shah ND, Bryant SC, Christianson TJ, Bjornsen SS, Giesler PD,
Krause K, Erwin PJ, Montori VM, Evidens Research Group: Chronic care
model and shared care in diabetes: randomized trial of an electronic
decision support system. Mayo Clin Proc 2008, 83:747-757.
36. O’Connor PJ, Sperl-Hillen J, Johnson PE, Rush WA, Crain AL: Customized
feedback to patients and providers failed to improve safety or quality of
diabetes care: a randomized trial. Diabetes Care 2009, 32:1158-1163.
37. Renders CM, Valk GD, Griffin SJ, Wagner EH, Eijk Van JT, Assendelft WJ:
Interventions to improve the management of diabetes in primary care,
outpatient, and community settings: a systematic review. Diabetes Care
2001, 24:1821-1833.
38. Hysong SJ: Meta-analysis: audit and feedback features impact
effectiveness on care quality. Med Care 2009, 47:356-363.
39. Debacker N, Nobels F, Vandenberghe H, Van Crombrugge P, Scheen A, Van
Casteren V: Organization of a quality-assurance project in all Belgian
multidisciplinary diabetes centres treating insulin-treated diabetes
patients: 5 years’ experience. Diabet Med 2008, 25:179-185.
40. Debacker N, Van Crombrugge P, Sourdeau L, Libeer J, Van Casteren V,
Scheen A, Nobels F: A nationwide external quality assessment
programme for HbA1c in Belgium: an example of a quality cycle
[abstract]. Diabetic Medicine 2006, 23(Suppl 4):5-199.




Cite this article as: Nobels et al.: Study rationale and design of
OPTIMISE, a randomised controlled trial on the effect of benchmarking
on quality of care in type 2 diabetes mellitus. Cardiovascular Diabetology
2011 10:82.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Nobels et al. Cardiovascular Diabetology 2011, 10:82
http://www.cardiab.com/content/10/1/82
Page 10 of 10
